Back to results
US 12,605,436 B2Granted
Chikungunya vaccine formulations
AssigneeValneva SE
InventorsChristoph Reinisch, Robert Schlegl, Jürgen Heindl-Wruss
Life of this patent
Estimating the term…
Abstract
The present invention is related to novel liquid and lyophilized formulations of Chikungunya virus useful as vaccines and methods for their preparation.
Claims20
A lyophilized live chikungunya vaccine formulation lyophilized from a composition comprising:
- a) an effective amount of at least one strain of live chikungunya virus;
- b) 1% to 20% (w/v) sugar;
- c) 1 mM to 20 mM phosphate;
- d) 1 mM to 50 mM of at least one carboxylate buffering agent;
- e) 1 mM to 10 mM MgCl2;
- f) 0.1% to 5% (w/v) D-sorbitol;
- g) 1 mM to 20 mM L-methionine;
- and h) 0.001% to 0.1% (w/v) human serum albumin (HSA), wherein said at least one strain of live chikungunya virus is selected from an attenuated chikungunya virus of SEQ ID NO:
- 1;
- variants with 99% sequence identity to SEQ ID NO:
- 1, wherein said variant also has the 60 aa deletion as in SEQ ID NO:
- 1;
- and/or combinations thereof.
10 more elements
A method of preparing a lyophilized chikungunya formulation, comprising:
- (i) cultivating a chikungunya virus and mixing the chikungunya virus with a concentrated stabilizing solution to form a virus bulk (i);
- and, optionally,
- (ii) dialyzing the virus bulk (i) to form a composition (ii);
- wherein said composition (ii) comprises a) 1% to 20% (w/v) sugar;
- b) 1 mM to 20 mM phosphate;
- c) 1 mM to 50 mM of at least one carboxylate;
- d) 1 mM to 10 mM MgCl2;
- e) 0.1% to 5% (w/v) D-sorbitol;
- g) 1 mM to 20 mM L-methionine;
- and f) 0.001% to 0.1% (w/v) human serum albumin (HSA);
- and
- (iii) lyophilizing said virus bulk (i) or composition (ii).
9 more elements
Dependencies are inferred from the claim text.